Viewing Study NCT00340990



Ignite Creation Date: 2024-05-05 @ 4:54 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00340990
Status: COMPLETED
Last Update Posted: 2019-12-05
First Post: 2006-06-19

Brief Title: Immune Responses to Mycobacterium Tuberculosis
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institutes of Health Clinical Center CC

Study Overview

Official Title: Pilot Study of CD4 T Cell Immune Responses to Mycobacterium Tuberculosis
Status: COMPLETED
Status Verified Date: 2015-11-27
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study conducted at the University of Mali in the capital city of Bamako will investigate how the body reacts to infection with Mycobacterium tuberculosis MTB the organism that causes tuberculosis Tuberculosis is a major global health problem whose solution requires development of an effective vaccine However incomplete understanding of how immunity to MTB is acquired and measured limits vaccine development This study will focus on certain immune system cells - CD4 T cells - that appear to be very important in fighting tuberculosis

Individuals 16 years of age and older who have or have not been exposed to either tuberculosis or HIV or both may be eligible for this study Candidates will be screened with a medical history physical examination blood tests review of medical records and laboratory tests and if medically indicated a chest x-ray Individuals whose medical records indicate a past history of tuberculosis or a positive test for exposure to tuberculosis will have a tuberculin skin test For this test a few drops of fluid are placed under the skin to see if the immune system reacts to the substance indicating previous exposure to MTB

Participants will come to the University of Mali 10 times over a 1-year period - 7 times within the first 3 months of the study and then once every 3 months until 1 year after enrollment At each study visit they will be asked about their medical history and will donate 75 milliliters about 13 cup of blood totaling 830 mL over the entire year More blood may be requested if the participants immune system reacts strongly to MTB in laboratory tests No more than 450 mL 2 cups of blood would be collected every 6 weeks this amount is the Red Cross limit for regular blood donations every 6 weeks

The blood samples will be used for tests that measure the level of immunity to tuberculosis Genetic tests may be performed on blood cells to help interpret special tests of immunity Because HIV-infected people are included in the study the findings may also provide information on how HIV renders vulnerability to opportunistic infections including tuberculosis
Detailed Description: Tuberculosis is a daunting global health problem The solution requires development of an effective vaccine But incomplete understanding of Mycobacterium tuberculosis MTB immunity-how it is acquired how it is measured-limits vaccine development to empiric rather than rational approaches New perspectives are needed Most individuals infected with MTB never actually develop active tuberculosis Similarly most individuals with treated tuberculosis or BCG vaccination are also protected from subsequent disease These individuals may be said to be immune One approach to obtaining greater understanding of MTB immunity is to study these individuals to discover mechanisms of immunity that mediate their protection from disease Because it is already known that CD4 T cells are a critical component of MTB immunity studying CD4 T cell responses to MTB infection in immune individuals is a reasonable starting point To determine which CD4 T cell subsets and which CD4 T cell immune responses are important we will compare individuals with prior exposure immunity to MTB to individuals with active tuberculosis Because HIV infection interferes with the CD4 T cell response to MTB it dramatically increases the risks for acquiring MTB infection and for developing disease Under these circumstances it is easier to discern mechanisms relevant to MTB immunity because of exaggerated MTB-specific responses In this study we aim to identify CD4 T cell subsets and responses that correlate with MTB immunity We anticipate that these correlations will yield new insight into mechanisms of MTB immunity that will be relevant to vaccine development In addition by examining MTB immunity in the setting of HIV coinfection we anticipate new insights into mechanisms of how HIV causes disease

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
04-I-N009 None None None